FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056233231> ?p ?o ?g. }

• W2056233231 endingPage "472" @default.
• W2056233231 startingPage "466" @default.
• W2056233231 abstract "Recent reports suggest that Clostridium difficile colitis may be evolving into a more severe disease. During the second half of 2002 we noted an increase in the number of patients with severe C. difficile-associated diarrhea (CDAD) in our institution. We describe cases of CDAD at our institution over a 13-year period and investigate changes in illness severity.We undertook a retrospective chart review of all cases of CDAD diagnosed at the Centre hospitalier universitaire de Sherbrooke from Jan. 1, 1991, to Dec. 31, 2003. Because the hospital serves a well-defined population of Quebec, we were also able to calculate population-based incidence during this period. We abstracted data on individual patients from patient charts and from hospital and pharmacy computer databases. We defined cases of CDAD as having a positive C. difficile cytotoxicity assay result, or endoscopic or histopathological evidence of pseudomembranous colitis. A case was considered complicated if one or more of the following was observed: megacolon, perforation, colectomy, shock requiring vasopressor therapy, or death within 30 days after diagnosis.A total of 1721 cases of CDAD were diagnosed during the study period. The incidence increased from 35.6 per 100,000 population in 1991 to 156.3 per 100,000 in 2003; among patients aged 65 years or more, it increased from 102.0 to 866.5 per 100,000. The proportion of cases that were complicated increased from 7.1% (12/169) in 1991-1992 to 18.2% (71/390) in 2003 (p < 0.001), and the proportion of patients who died within 30 days after diagnosis increased from 4.7% (8/169) in 1991-1992 to 13.8% (54/390) in 2003 (p < 0.001). A high leukocyte count (20.0 small ha, Cyrillic 10(9)/L or greater) and an elevated creatinine level (200 micromol/L or greater) were strongly associated with adverse outcomes: in 2003, 45 (40.9%) of 110 patients with a high leukocyte count or creatinine level, or both, had complicated CDAD and 28 (25.5%) died within 30 days after diagnosis. After adjustment for age and other confounding factors, patients initially given oral vancomycin therapy had a risk of progression to complicated CDAD that was 79% lower than the risk among patients initially treated with metronidazole (adjusted odds ratio 0.2, 95% confidence interval 0.06-0.8, p = 0.02).An epidemic of CDAD with an increased case-fatality rate has had important consequences on the elderly population of our region. Our observational data suggest that the equivalence of vancomycin and metronidazole in the treatment of CDAD needs to be questioned." @default.
• W2056233231 created "2016-06-24" @default.
• W2056233231 creator A5000291063 @default.
• W2056233231 creator A5002853617 @default.
• W2056233231 creator A5010148072 @default.
• W2056233231 creator A5029293286 @default.
• W2056233231 creator A5031335900 @default.
• W2056233231 creator A5032616259 @default.
• W2056233231 creator A5057122476 @default.
• W2056233231 creator A5084495161 @default.
• W2056233231 date "2004-08-31" @default.
• W2056233231 modified "2023-10-14" @default.
• W2056233231 title "Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity" @default.
• W2056233231 cites W2005821353 @default.
• W2056233231 cites W2025939938 @default.
• W2056233231 cites W2058867048 @default.
• W2056233231 cites W2062482987 @default.
• W2056233231 cites W2071830631 @default.
• W2056233231 cites W2072995469 @default.
• W2056233231 cites W2080394999 @default.
• W2056233231 cites W2103124900 @default.
• W2056233231 cites W2108693491 @default.
• W2056233231 cites W2116573698 @default.
• W2056233231 cites W2117463772 @default.
• W2056233231 cites W2122546651 @default.
• W2056233231 cites W2123831499 @default.
• W2056233231 cites W2124167692 @default.
• W2056233231 cites W2126927211 @default.
• W2056233231 cites W2128205055 @default.
• W2056233231 cites W2152531094 @default.
• W2056233231 cites W2153996209 @default.
• W2056233231 cites W2157190807 @default.
• W2056233231 cites W2158106947 @default.
• W2056233231 cites W2167717276 @default.
• W2056233231 cites W2277430674 @default.
• W2056233231 cites W2278860867 @default.
• W2056233231 cites W2318911370 @default.
• W2056233231 cites W2339574580 @default.
• W2056233231 cites W2341427843 @default.
• W2056233231 cites W2393115371 @default.
• W2056233231 cites W4251610426 @default.
• W2056233231 doi "https://doi.org/10.1503/cmaj.1041104" @default.
• W2056233231 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/514643" @default.
• W2056233231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15337727" @default.
• W2056233231 hasPublicationYear "2004" @default.
• W2056233231 type Work @default.
• W2056233231 sameAs 2056233231 @default.
• W2056233231 citedByCount "1058" @default.
• W2056233231 countsByYear W20562332312012 @default.
• W2056233231 countsByYear W20562332312013 @default.
• W2056233231 countsByYear W20562332312014 @default.
• W2056233231 countsByYear W20562332312015 @default.
• W2056233231 countsByYear W20562332312016 @default.
• W2056233231 countsByYear W20562332312017 @default.
• W2056233231 countsByYear W20562332312018 @default.
• W2056233231 countsByYear W20562332312019 @default.
• W2056233231 countsByYear W20562332312020 @default.
• W2056233231 countsByYear W20562332312021 @default.
• W2056233231 countsByYear W20562332312022 @default.
• W2056233231 countsByYear W20562332312023 @default.
• W2056233231 crossrefType "journal-article" @default.
• W2056233231 hasAuthorship W2056233231A5000291063 @default.
• W2056233231 hasAuthorship W2056233231A5002853617 @default.
• W2056233231 hasAuthorship W2056233231A5010148072 @default.
• W2056233231 hasAuthorship W2056233231A5029293286 @default.
• W2056233231 hasAuthorship W2056233231A5031335900 @default.
• W2056233231 hasAuthorship W2056233231A5032616259 @default.
• W2056233231 hasAuthorship W2056233231A5057122476 @default.
• W2056233231 hasAuthorship W2056233231A5084495161 @default.
• W2056233231 hasBestOaLocation W20562332311 @default.
• W2056233231 hasConcept C120665830 @default.
• W2056233231 hasConcept C121332964 @default.
• W2056233231 hasConcept C126322002 @default.
• W2056233231 hasConcept C141071460 @default.
• W2056233231 hasConcept C167135981 @default.
• W2056233231 hasConcept C187212893 @default.
• W2056233231 hasConcept C191897082 @default.
• W2056233231 hasConcept C192562407 @default.
• W2056233231 hasConcept C2775862500 @default.
• W2056233231 hasConcept C2776258884 @default.
• W2056233231 hasConcept C2776611563 @default.
• W2056233231 hasConcept C2776667177 @default.
• W2056233231 hasConcept C2778456384 @default.
• W2056233231 hasConcept C2778527123 @default.
• W2056233231 hasConcept C2779134260 @default.
• W2056233231 hasConcept C2779802037 @default.
• W2056233231 hasConcept C2780479503 @default.
• W2056233231 hasConcept C2908647359 @default.
• W2056233231 hasConcept C2991793726 @default.
• W2056233231 hasConcept C2994496256 @default.
• W2056233231 hasConcept C501593827 @default.
• W2056233231 hasConcept C61511704 @default.
• W2056233231 hasConcept C71924100 @default.
• W2056233231 hasConcept C86803240 @default.
• W2056233231 hasConcept C89423630 @default.
• W2056233231 hasConcept C99454951 @default.
• W2056233231 hasConceptScore W2056233231C120665830 @default.
• W2056233231 hasConceptScore W2056233231C121332964 @default.

• next